The start of 2023 has seen a number of firms across the off-patent industry announce management changes, with multiple appointments at Sandoz, a new CFO at Stada, a fresh CSO at Mallinckrodt, new generics leadership at Orion and board changes at Viatris and EuroAPI.

Teligent CEO Jason Grenfell-Gardner has stepped down with immediate effect, while Centrient CEO Karl Rotthier is preparing to leave the role in March. Both firms have announced details of their replacements. Meanwhile, Stada has appointed a new chief financial officer.

Clear progress is being made in the European value added medicines sector, Medicines for Europe’s outgoing sector chair Arun Narayan has highlighted in an interview with Generics Bulletin. However, there is still more work to be done to ensure that the market is supported by imminent legislative and regulatory initiatives.